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ABSTRACT
ARID1A mutations are observed in various tumors, including ovarian clear cell 
(OCCC) and endometrioid carcinomas, endometrial, and breast carcinomas. They 
commonly result in loss of ARID1A-protein expression and frequently co-occur with 
PI3K/AKT-pathway activating mechanisms. The aim of this study was to test the 
hypothesis as to whether PI3K/AKT-pathway activation is a critical mechanism in 
ARID1A-mutated tumors and if consequently ARID1A-deficient tumors show increased 
sensitivity to treatment with PI3K- and AKT-inhibitors. Upon ARID1A knockdown, 
MCF7 breast cancer cells and primary MRC5 cells exhibited a significantly increased 
sensitivity towards the AKT-inhibitors MK-2206 and perifosine, as well as the PI3K-
inhibitor buparlisib. Knockdown of ARID1A in MCF7 led to an increase of pAKT-Ser473. 
AKT-inhibition with MK-2206 led to increased apoptosis and to a decrease of pS6K in 
ARID1A-depleted MCF7 cells but not in the controls. In five OCCC cell lines ARID1A-
deficiency correlated with increased pAKT-Ser473 levels and with sensitivity towards 
treatment with the AKT-inhibitor MK-2206. In conclusion, ARID1A-deficient cancer 
cells demonstrate an increased sensitivity to treatment with small molecule inhibitors 
of the PI3K/AKT-pathway. These findings suggest a specific requirement of the PI3K/
AKT pathway in ARID1A-deficient tumors and reveal a synthetic lethal interaction 
between loss of ARID1A expression and inhibition of the PI3K/AKT pathway. 
INTRODUCTION
Mutations in the gene encoding the AT-rich 
interacting domain containing protein 1A (ARID1A) are 
frequently observed in a wide variety of gynecological 
and non-gynecological cancers [1, 2]. These occur in 
approximately 50% of endometriosis-associated ovarian 
clear cell (OCCC) and 30% of endometrioid ovarian 
carcinomas (EnOC) [3, 4], in endometrial carcinomas, 
with a loss of expression in 20-30% depending on the 
histological subtype [5, 6], as well as in breast carcinomas 
(mutations in 4-35%) [7, 8]. Non-gynecological 
carcinomas with frequent ARID1A mutations include 
pancreatic carcinomas (mutations in 8-45%) [9, 10], 
gastric adenocarcinomas (mutations in 8-29%) [11-
13], hepatocellular carcinomas (mutations in 10-17%) 
[14-16], as well as clear cell renal cell carcinomas [17, 
18]. The majority of the mutations lead to a loss of the 
ARID1A encoded protein [3], also referred to as BAF250a 
or p270, which is a subunit of the SWI/SNF chromatin 
remodeling complex [2]. Although ARID1A has recently 
been identified as a bona fide tumor suppressor gene and 
is currently being intensively investigated, the knowledge 
about the function and the consequences of a loss of 
expression of this protein is relatively limited [2]. 
Interestingly, ARID1A mutations frequently 
coexist with activating mutations of PIK3CA [12, 19] 
and/or loss of PTEN expression [20], which both lead 
to a downstream activation of the PI3K/AKT pathway. 
Furthermore, it has recently been shown in endometrial 
cancer that loss of ARID1A expression leads to an 
increased phosphorylation of AKT at Ser-473[21]. 
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Similarly, increased AKT phosphorylation has also been 
reported in OCCC tissue samples with loss of ARID1A 
expression when concomitant PIK3CA mutations and loss 
of PTEN expression were excluded [22]. 
These observations strongly suggest 
interdependency between ARID1A mutations and PI3K/
AKT pathway activation, indicating that tumor cells 
with loss of ARID1A expression may be dependent on 
constitutive activation of the PI3K/AKT-pathway and 
consequently may also be more vulnerable to its inhibition 
[23]. This is of considerable clinical relevance since loss 
of ARID1A expression may be predictive for a favorable 
treatment response to small molecule inhibitors of the 
PI3K/AKT-pathway, which are currently under clinical 
investigation. 
In this study, we demonstrate that depletion of 
ARID1A protein expression significantly increases 
the sensitivity of cancer cells towards PI3K- and AKT-
inhibitors, which is reflected by increased rates of 
apoptosis in treated ARID1A-depleted cells. Our findings 
suggest a dependency of ARID1A-mutated tumors on 
activating mechanisms of the PI3K/AKT-pathway, which 
may be exploited therapeutically.
RESULTS
ARID1A-deficient cell lines demonstrate increased 
sensitivity to treatment with the AKT-inhibitors 
MK-2206 and perifosine
ARID1A-depleted MCF7 cells were found to be 
significantly more sensitive to treatment with the AKT-
inhibitors MK-2206 and perifosine, as demonstrated 
in Figure 1a and 1b. The LogIC50 values for treatment 
with MK-2206 were -7.411 ±0.211 in ARID1A-depleted 
MCF7 cells, when compared to -4.841 ±0.273 in the 
controls (p<0.0001). This represents a more than 370-
fold increased AKT inhibitor sensitivity of ARID1A-
depleted MCF7 cells as compared to the wild-type control. 
LogIC50 for perifosine in ARID1A-depleted MCF7 cells 
was -4.984 ±0.133, compared to the LogIC50 of -3.774 
±0.423 (p=0.0001) for the controls, which means an 
approximately 16-fold increased sensitivity. 
We performed the same experiment in the primary 
fibroblast cell line MRC5 to verify our observations in a 
cell line without any oncogenic mutations and, similarly, 
we found an increased sensitivity of ARID1A-depleted 
MRC5 cells towards treatment with MK-2206 with 
LogIC50 of -6.307 ±0.173 as compared to -5.316 ±0.236 
for the control (p=0.002). This meant an approximately 10-
fold increase in sensitivity. For treatment with perifosine 
the LogIC50 values were -5.867 ±0.135 in ARID1A-
depleted MRC5 cells, as compared to -5.024 ±0.199 in 
the controls: equivalent to an increase in sensitivity of 
approximately 7-fold in ARID1A-depleted MRC5 cells 
(p=0.004).
As a control, no significant difference in sensitivity 
to treatment with MK-2206 or perifosine was found in 
the ARID1A-deficient OCCC cell line OVSAYO after 
transfection with ARID1A siRNA.
ARID1A-deficient cell lines demonstrate increased 
sensitivity to treatment with the PI3K-inhibitor 
buparlisib 
The sensitivity to treatment with the PI3K inhibitor 
buparlisib in ARID1A-depleted MCF7 and MRC5 cells 
was shown to increase significantly with comparison to the 
controls, but less pronounced than for inhibition of AKT 
(Figure 1c). The LogIC50 values were -6.780 ±0.150 for 
ARID1A-depleted MCF7 cells, as compared to -6.252 
±0.184 for the controls (approximately a 3-fold increase; 
p=0.025) and -6.712 ±0.154 for ARID1A-depleted MRC5 
as compared to -5.950 ±0.128 for the controls (p=0.002), 
representing an almost 6-fold increase in sensitivity. 
The ARID1A-deficient control cell line, OVSAYO, did 
not show an increased sensitivity for buparlisib upon 
transfection with ARID1A siRNA.
Loss of ARID1A expression increases AKT 
phosphorylation at Ser-473 and downstream 
phosphorylation of p70 S6 kinase in MCF7 and 
MRC5 cells
First, we verified that loss of ARID1A increases 
phosphorylation of AKT at Ser-473 (pAKT-Ser473) as has 
been described in endometrial cancer cell lines [21]. In 
both MCF7 and MRC5 cell lines, ARID1A knockdown by 
siRNA led to an increased phosphorylation of pAKT-Ser473 
as well as an increased downstream phosphorylation of 
p70S6kinase (pS6K) as shown in Figure 2a and 2b.
AKT-inhibition leads to apoptosis in ARID1A-
deficient cells
We next investigated if inhibition of AKT leads 
to increased apoptosis in ARID1A-deficient cells. No 
cleavage of PARP1 (a marker of apoptosis) was observed 
in the MCF7 control cells (transfected with siLUC) with 
or without treatment with the AKT-inhibitor, MK-2206. 
In contrast, PARP1 cleavage was discretely detectable in 
ARID1A-depleted MCF7 cells and substantially increased 
after treatment with the AKT-inhibitor MK-2206 (Figure 
2a). Similar observations were made for MRC5 (Figure 
2b). Consistently, using a TUNEL-assay technique we 
found that apoptosis was markedly increased in ARID1A-
depleted MCF7 and MRC5 cells treated with MK-2206, 
in comparison to the control cells that expressed normal 
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levels of ARID1A (Figure 3). Upon siARID1A transfection 
and treatment with MK-2206, PARP1 cleavage was not 
increased in the ARID1A-deficient control cell line, 
OVSAYO, which confirmed that the increased apoptosis 
rate in response to the AKT-inhibitor treatment was 
specifically due to the knockdown of the ARID1A gene 
and not to other unspecific factors that would be indirectly 
related to the transfection method (Figure 2c).
Knockdown of AKT abrogates the increased 
proliferation rate of ARID1A-depleted MCF7 
cells
ARID1A depletion led to an increased proliferation 
of MCF7 cells in comparison to the controls (Figure 2d). 
Knockdown of only AKT1 reduced measurable pAKT-
Ser473- and AKT- levels, and led to a decreased level of 
pS6K, but did not lead to a difference in the amount of 
viable MCF7 cells after 5 days (Figure 2d, 2e). In contrast, 
combined knockdown of ARID1A and AKT1 completely 
abrogated the increased proliferation in ARID1A-depleted 
MCF7 cells (Figure 2d).
Sensitivity to treatment with MK-2206 in OCCC
Loss of ARID1A expression correlated with 
increased pAKT-Ser473 in five OCCC cell lines (Figure 
4b, 4c). The cell lines, OVSAYO, OVISE, and HCH-1, 
did not express detectable levels of ARID1A and showed 
high sensitivity towards treatment with the AKT-inhibitor, 
MK-2206, whereas the two OCCC cell lines with intact 
ARID1A expression were resistant towards the same 
Figure 1: Loss of ARID1A expression leads to increased sensitivity towards the AKT-inhibitors MK-2206 and perifosine 
as well as towards the PI3K-inhibitor buparlisib in MCF7 and MRC5 cells. (A) Increased sensitivity of ARID1A-depleted 
MCF7 and MRC5 cells towards the AKT-inhibitor MK-2206. (B) Increased sensitivity of ARID1A-depleted MCF7 and MRC5 cells 
towards the AKT-inhibitor perifosine. (C) Increased sensitivity of ARID1A-depleted MCF7 and MRC5 cells towards the PI3K-inhibitor 
buparlisib. The ARID1A-deficient OVSAYO cell line served as a control in all the experiments. The p-values indicate the divergence of the 
IC50-values calculated by an F-test. Significance was assumed for p<0.05 and is indicated in the figures (ns: not significant).
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Figure 2: Loss of ARID1A expression increases vulnerability of cancer and primary cells to AKT-inhibition resulting 
in increased apoptosis. (A) Immunoblot showing an increased phosphorylation of AKT at Ser-473 in response to knockdown of 
ARID1A by siRNAs in the MCF7 cell line. ARID1A depletion increased pS6K downstream. Treatment with the AKT-inhibitor MK-2206 
(at a concentration of 10-6M) completely abrogated pAKT-Ser473 in ARID1A-deficient MCF7 cells and led to reduced pS6K, in contrast to 
the controls where pS6K was not reduced. PARP-1 cleavage was markedly increased in ARID1A-deficient MCF7 cells treated with MK-
2206 indicating an increased apoptosis rate, in contrast to the controls where no increase of the apoptosis rate was detectable after treatment 
with MK-2206. (B) Immunoblot demonstrating ARID1A knockdown in MRC5 cell line. The relative level of pAKT-Ser473 compared to the 
respective AKT level was increased in ARID1A-depleted MRC5 cells and completely abrogated by the treatment with the AKT-inhibitor 
MK-2206 (10-6M). (C) Immunoblot demonstrating the effects of a treatment with the AKT-inhibitor MK-2206 (10-6M) in the ARID1A-
deficient OCCC cell line OVSAYO, which was used as a negative control for the knockdown experiments. Knockdown of ARID1A by 
siRNAs did not show an effect on pAKT-Ser473 and PARP-1 cleavage in this cell line, confirming that the effects are specifically due to 
the knockdown of the ARID1A gene. Combination of ARID1A-knockdown and treatment with MK-2206 did not cause increased PARP-
1 cleavage in this control cell line. (D) MCF7 cells were seeded in 96-well plates and transfected with siLUC, siAKT1, siARID1A, or 
double-transfected with siAKT1 and siARID1A. Viable cells were counted with an MTS assay after 5 days (indicated as percent of viable 
cells in relation to the siLUC-transfected controls). ARID1A knockdown led to an increased proliferation of MCF7 cells in comparison 
to the controls. Knockdown of only AKT1 did reduce measurable pAKT-Ser473- and AKT- levels and led to a decreased level of pS6K (as 
shown in (E)), but did not lead to a difference in the amount of viable MCF7 cells. Combined knockdown with AKT1 in contrast completely 
abrogated the increased proliferation in ARID1A-depleted MCF7 cells. (E) Western blot showing the decreased expression of pAKT-Ser473, 
AKT, and pS6K 120h after AKT1-siRNA knockdown in MCF7 cells. 
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Figure 3: Treatment with the AKT-inhibitor MK-2206 causes apoptosis in ARID1A-depleted MCF7 and MRC5 cells. 
Treatment with MK-2206 (10-6M) for 48h led to an increased rate of apoptotic cells in ARID1A-depleted MCF7 and MRC5 cells compared 
to the controls. Note the different staining pattern of apoptotic cells compared to the positive controls, which is caused by pyknosis and/or 
fragmentation of the nuclei in the apoptotic cells (indicated by red arrows). The more homogeneous staining in the positive controls is the 
result of treatment of intact nuclei of fixated non-apoptotic cells with DNase immediately prior to the addition of the TUNEL incubation 
mix. Negative controls were obtained by omission of the TUNEL enzyme in the incubation mix. The nuclei are represented in blue (DAPI 
staining) and the fluorescein signal is labelled in red-glow.
Figure 4: Loss of ARID1A expression is associated with high sensitivity to the AKT-inhibitor MK-2206 in ovarian clear 
cell carcinoma cell lines. (A) The three ARID1A-deficient OCCC cell lines OVSAYO, OVISE, and HCH-1 were highly sensitive to 
a treatment with MK-2206 whereas the two OCCC cell lines ES-2 and RMG-1 with intact ARID1A expression were resistant to the same 
treatment. The logIC50 values significantly differed between ARID1A-intact and ARID1A-deficient OCCC cell lines (***p<0.0001) as 
verified with an F-test (Graph Pad Prism, version 6). (B) Immunoblot showing intact ARID1A expression in ES-2 and RMG-1 and loss of 
ARID1A expression in OVSAYO, OVISE, and HCH-1. Treatment with MK-2206 (10-6M) completely abrogated detectable pAKT-Ser473 
levels in all OCCC cell lines. (C) Densitometric quantification of the relative pAKT-Ser473/AKT expression in the five untreated and treated 
OCCC cell lines (ImageJ version 1.46, NIH, USA). Relative pAKT-Ser473/AKT levels were significantly increased in the three ARID1A-
deficient OCCC cell lines OVSAYO, OVISE, and HCH-1, as compared to the two ARID1A-intact OCCC cell lines ES-2 and RMG-1 
(*p<0.01) as verified by a t-test (Graph Pad Prism, version 6).
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treatment (Figure 4a). 
DISCUSSION
The results of this study demonstrate an 
interdependency of ARID1A and the PI3K/AKT 
pathway, which results in significantly increased 
sensitivity of ARID1A-deficient cancer cells to PI3K- 
and AKT- inhibition. We thus demonstrate for the first 
time a principle of synthetic lethality between ARID1A 
deficiency and inhibition of the PI3K/AKT pathway in 
two cellular model systems. MCF7 is a well-established 
breast carcinoma cell line and MRC5 a commonly used 
human primary lung fibroblast cell line. Although MCF7 
contains a moderately activating mutation of PIK3CA 
[24, 25], depletion of ARID1A by siRNA considerably 
increased phosphorylation of AKT at Ser-473 in this cell 
line, as described previously in endometrial carcinoma cell 
lines [21]. The normal primary fibroblast cell line, MRC5, 
that does not contain any known mutations [26] confirmed 
our results, thus minimizing the likelihood of secondary 
effects by other mutations in the ARID1A knockdown 
experiments. 
Mutations in the ARID1A gene are a frequent event 
occurring in a wide variety of gynecological and non-
gynecological cancers [23]. They usually lead to a loss 
of expression of the ARID1A encoded protein [3], and 
are thus not directly targetable [2]. Indirect therapeutic 
approaches using the principle of synthetic lethality in 
regard to members of the SWI/SNF chromatin remodeling 
complexes are an appropriate alternative strategy [27, 
28]. Thus, a recent study demonstrated a synthetic 
lethal relationship between inactivating mutations of the 
homologs ARID1A and ARID1B, both in primary and 
cancer cells. ARID1B depletion in the context of loss 
of ARID1A expression led to a significant decrease in 
cell proliferation revealing this homologue as a relative 
vulnerability in ARID1A-mutant cell lines. Despite the 
substantial relevance of these observations for potential 
future approaches, the immediate clinical relevance 
is limited due to the fact that there are currently no 
substances available that would therapeutically inhibit 
ARID1B expression [28].
An interdependency between ARID1A mutations and 
PIK3CA is strongly supported by the supplementary data 
of the study of Helming et al., since PIK3CA (just after 
ARID1B) scored as the second top candidate preferentially 
necessary for the growth of ARID1A-mutated cancer cell 
lines in the project, ‘Achilles’ [28]. A dependency of 
ARID1A-mutated tumors on activation of the PI3K/AKT 
pathway is further supported by a study in ARID1A-
knockout and ARID1A/PTEN-double-knockout mice, 
where it was observed that only mice with simultaneous 
loss of ARID1A and PTEN expression developed poorly 
differentiated ovarian tumors, in contrast to mice with loss 
of only ARID1A that did not develop ovarian tumors [29]. 
This indicates that ARID1A-mutated cell clones require 
a second-hit mutation in order to transform into cancer, 
which may explain why loss of ARID1A expression 
was observable in a subset of non-atypical benign 
endometriosis in one of our previous studies [30]. 
Interestingly, ARID1A-mutated OCCC have been 
reported to be associated with resistance to conventional 
platinum-based chemotherapy regimens in a recent study 
[31]. If this observation is confirmed in larger collectives, 
an analysis of the ARID1A expression status, which is 
easily feasible by immunohistochemistry, will possibly 
become an important predictive tool to assess the 
probability of resistance to conventional platinum based 
chemotherapy and, as we suggest in this study, increased 
sensitivity to PI3K- and/or AKT-inhibitors. PI3K/AKT-
inhibitors, which are a promising tool to overcome 
chemotherapy resistance, may be selectively added to 
the treatment strategy in patients with ARID1A-deficient 
tumors.
In conclusion, ARID1A deficiency leads to a 
significantly increased sensitivity towards PI3K- and 
AKT-inhibition in tumor cells in vitro. The findings 
suggest a specific requirement of the PI3K/AKT pathway 
in ARID1A-deficient cancer cells and reveal a synthetic 
lethal interaction between loss of ARID1A expression and 
inhibition of the PI3K/AKT pathway.
MATERIAL AND METHODS
Cell culture
The breast carcinoma cell line MCF7 (E. 
Felley-Bosco, Switzerland) and the human primary 
lung fibroblasts MRC5 (ATCC) were grown in 
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, 
LifeTechnologies, Thermo Fisher Scientific Inc., 
Waltham, MA, USA). The OCCC cell lines ES-2, RMG-1, 
OVSAYO, OVISE, HCH-1 (R. Natrajan, UK) were grown 
in RPMI 1640 medium (Gibco). All cell lines used in this 
study were verified by short tandem repeat (STR) DNA 
identity testing. All growing media were supplemented 
with 10% (v/v) fetal bovine serum (Gibco) and Antibiotic-
Antimycotic (containing penicillin, streptomycin and 
amphotericin B) (Gibco). Cell cultures were maintained 
at 37°C in a humidified atmosphere at 5% CO2. Cells were 
passaged at 90% confluency.
Transient siRNA transfections
Transient knockdown of ARID1A was performed 
with four different ARID1A siRNAs (J-017263-05, -06, 
-07, and -08, ON-TARGETplus Human ARID1A siRNA, 
Dharmacon, Thermo Scientific, Thermo Fisher Scientific 
Inc., Waltham, MA, USA) using RNAimax (Gibco) 
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according to the manufacturer’s instructions. The control 
cells were transfected with siRNA against luciferase 
(sense): CGUACGCGGAAUACUUCGATTdTd 
(Microsynth AG, Baldach, Switzerland). The AKT1 
knockdown control experiments were performed with 
a siRNA smart-pool (L-003000-00, ON-TARGET plus 
Human AKT1 (207) siRNA, Dharmacon). Cells were 
transfected overnight and the medium was replaced the 
following morning. The size of culture dishes and length 
of transfection is indicated for the specific experiments .
Treatment with AKT- and PI3K- inhibitors
The AKT-inhibitors MK-2206, perifosine, and 
the pan-PI3K-inhibitor buparlisib (BKM120) were all 
obtained from Selleckchem.com (Selleck Chemicals, 
Houston, TX, USA). The inhibitors were diluted according 
to the manufacturer’s protocol (MK-2206 and buparlisib 
in DMSO and perifosine in sterile ddH2O) and prepared 
freshly for each treatment. Vehicle substance was used in 
the highest corresponding concentration for the treatment 
of the controls.
Drug sensitivity assays
Drug sensitivity assays were performed according to 
the drug manufacturer’s recommendations (Selleckchem.
com). In brief, cells were seeded in 96-well plates at 
concentrations of 1000-2000 cells per well (MRC5 cells 
were seeded at a density of 10’000 cells per well). On the 
following day, cells were transiently transfected overnight 
with the corresponding siRNAs and then treated with 
the corresponding drugs at the indicated concentrations 
or vehicle substance as described above. Treatment was 
repeated after 2-3 days. After a total period of 4-5 days’ 
treatment, the medium was replaced by phenol-red free 
medium and the quantity of viable cells was assessed using 
a MTS assay (Cell Titer Aqueous, Promega, Madison, 
WI, USA) according to the manufacturer’s protocol. Plate 
absorbances were obtained using a spectrophotometer 
(Epoch Microplate Spectrophotometer, BioTek, Winooski, 
VT, USA). Each experiment was performed on at least 
two separate occasions for every unique ARID1A siRNA 
sequence and each of them run in triplicates.
Protein extraction and immunoblotting
Cells were seeded in 6cm culture dishes and 
transfected with the corresponding siRNAs the following 
day as described above, followed by the drug treatment 
where indicated. Whole-cell protein extracts were prepared 
from cells lysed before reaching confluence with an SDS 
lysis buffer. Western blotting was performed with primary 
antibodies against ARID1A (ab50878, Abcam, Cambridge, 
UK), AKT1 (#9272, Cell Signaling Technology, Danvers, 
MA, USA), phopho-Ser473-AKT (pAKT-Ser473) (#4058, 
Cell Signaling Technology), phospho-Thr421/Ser424-p70 
S6 Kinase (pS6K) (#9204, Cell Signaling Technology,), 
PARP-1 (#9542, Cell Signaling Technology), beta-
Actin (A5441, Sigma-Aldrich, Buchs SG, Switzerland). 
Incubation with the primary antibody was followed by 
incubation with a HRP-conjugated secondary antibody 
(anti-mouse and anti-rabbit HRP, Sigma-Aldrich) and 
chemiluminescent detection of proteins (Amersham, GE 
Healthcare Bio-Sciences, Pittsburgh, PA, USA).
TUNEL assay and fluorescence microscopy
A TUNEL assay (In Situ Cell Death Detection Kit, 
Fluorescein, Roche, Basel, Switzerland) based on labelling 
of DNA strand breaks was used to directly visualize 
apoptosis in the treated cell cultures. In brief, cells were 
directly plated on microscopy coverslips transfected with 
siRNAs and treated for 60h with MK-2206 or vehicle 
substance as described above. Positive controls were 
obtained by treatment of fixated non-apoptotic cells with 
30U/l recombinant DNase (in 1% (w/v) BSA / PBS) for 
1h immediately prior to the addition of the incubation 
mix. Negative controls were obtained by omission of the 
TUNEL enzyme in the incubation mix. The coverslips 
were mounted in DAPI mounting medium (Vectashield, 
Reactolab SA, Servion, Switzerland). A Leica DMI6000B 
microscope was used for analysis of the specimens.
Statistical analysis
Statistical analysis was performed with graph pad 
prism version 6 (GraphPad Software Inc., La Jolla, CA, 
USA). Results are expressed as mean ± standard error 
of the mean (SEM). Significance was assumed if p<0.05 
(F-test) in comparison to the respective controls.
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